Work

Supplementary Figures 1 through 3 from Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 1: Post-progresion survival based on initial PFS (6, 9, 12, and 15 months). Supplementary Figure 2: Radiographic example of isolated progression in one patient with acquired resistance to anti-PD-1. Supplementary Figure 3: Overall survival in the entire cohort

DOI: 10.1158/2326-6066.22537699

Authors: Daniel Y. Wang, Zeynep Eroglu, Alpaslan Ozgun, Paul D. Leger, Shilin Zhao, Fei Ye, Jason J. Luke, Richard W. Joseph, Rizwan Haq, Patrick A. Ott, F. Stephen Hodi, Jeffrey A. Sosman, Douglas B. Johnson, Elizabeth I. Buchbinder

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362600741

Cites:

Cited by:

Related to: 10